{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:59Z","timestamp":1782307859809,"version":"3.54.5"},"reference-count":23,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Real-world data on the therapeutic use of FLT3 inhibitors in Turkey remain limited. Therefore, we retrospectively evaluated outcomes from 13 academic centers nationwide, focusing on the multikinase inhibitor midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Methods: We collected comprehensive information regarding treatment efficacy, safety, and tolerability. Results: The overall response rate to intensive chemotherapy (3 + 7) plus midostaurin was 87.7%, with a complete remission rate of 84.2%, consistent with previously reported clinical trial results. Treatment discontinuation due to intolerance or toxicity was low (3.5%). One patient discontinued therapy because of septic shock during induction, and another due to a drug\u2013drug interaction during consolidation. Median overall survival was 21.4 months. Allogeneic stem cell transplantation was performed in first remission in 52.6% of patients. Five patients (8.8%) were refractory to induction therapy, and relapse occurred in 21.1% (12 patients). Conclusions: These findings support the effectiveness and acceptable tolerability of midostaurin in routine clinical practice for FLT3-mutated AML.<\/jats:p>","DOI":"10.3390\/jcm15020854","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T08:48:08Z","timestamp":1768985288000},"page":"854","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2957-2339","authenticated-orcid":false,"given":"Sema","family":"Se\u00e7ilmi\u015f","sequence":"first","affiliation":[{"name":"Hematology Clinic and Bone Marrow Transplantation Unit, Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-9206","authenticated-orcid":false,"given":"Sibel","family":"Kabuk\u00e7u Hac\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University, 20160 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-9555","authenticated-orcid":false,"given":"Fehmi","family":"Hindilerden","sequence":"additional","affiliation":[{"name":"Hematology and Apheresis Unit, Bak\u0131rk\u00f6y Dr. Sadi Konuk Education and Research Hospital, University of Health Sciences, 34147 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Turgut","sequence":"additional","affiliation":[{"name":"Division of Hematology, Tekirda\u011f Nam\u0131k Kemal University, 59030 Tekirda\u011f, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00fczg\u00fcn","family":"\u00d6zatl\u0131","sequence":"additional","affiliation":[{"name":"Division of Hematology, Ondokuz May\u0131s University, 55200 Samsun, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcls\u00fcm","family":"Akg\u00fcn \u00c7a\u011fl\u0131yan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University, 20160 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir","family":"Ba\u015ft\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Konya City Hospital, University of Health Sciences, 42020 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2868-665X","authenticated-orcid":false,"given":"Asl\u0131","family":"Y\u00fcksel \u00d6zt\u00fcrkmen","sequence":"additional","affiliation":[{"name":"Hematology and Apheresis Unit, Bak\u0131rk\u00f6y Dr. Sadi Konuk Education and Research Hospital, University of Health Sciences, 34147 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz","family":"Kat\u0131rc\u0131lar","sequence":"additional","affiliation":[{"name":"Hematology Clinic and Bone Marrow Transplantation Unit, Kayseri City Hospital, University of Health Sciences, 38080 Kayseri, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Namdaro\u011flu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Dokuz Eyl\u00fcl University, 35210 \u0130zmir, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba\u015fak","family":"\u00dcnver Koluman","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University, 20160 Denizli, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenk","family":"Sunu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sakarya University, 54187 Sakarya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Korkmaz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Konya City Hospital, University of Health Sciences, 42020 Konya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-8104","authenticated-orcid":false,"given":"Ay\u015fe","family":"Uysal","sequence":"additional","affiliation":[{"name":"Division of Hematology, F\u0131rat University, 23119 Elaz\u0131\u011f, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Bilen","sequence":"additional","affiliation":[{"name":"Value Added Medicine Medicalpark Bursa Hospital, \u0130stinye University, 16220, Bursa, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"Erkurt","sequence":"additional","affiliation":[{"name":"Division of Hematology, \u0130n\u00f6n\u00fc University, 44280 Malatya, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[{"name":"Hematology Clinic and Bone Marrow Transplantation Unit, Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Ula\u015f","sequence":"additional","affiliation":[{"name":"Hematology Clinic and Bone Marrow Transplantation Unit, Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altunta\u015f","sequence":"additional","affiliation":[{"name":"Hematology Clinic and Bone Marrow Transplantation Unit, Dr. Abdurrahman Yurtaslan Oncology Education and Research Hospital, University of Health Sciences, 06200 Ankara, T\u00fcrkiye"},{"name":"Division of Hematology, Department of Internal Medicine, School of Medicine, Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, 06800 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"7","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ferrara, F., Lessi, F., Vitagliano, O., Birkenghi, E., and Rossi, G. (2019). Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. Cancers, 11.","DOI":"10.3390\/cancers11020224"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5045\/br.2015.50.4.204","article-title":"Nationwide statistical analysis of myeloid malignancies in Korea: Incidence and survival rate from 1999 to 2012","volume":"50","author":"Park","year":"2015","journal-title":"Blood Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: Biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41375-021-01179-4","article-title":"Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: The Alliance CALGB 10603\/RATIFY trial","volume":"35","author":"Larson","year":"2021","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","first-page":"2580","article-title":"The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603\/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations","volume":"130","author":"Stone","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: Its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"Weber","year":"2022","journal-title":"Blood Adv."},{"key":"ref_13","unstructured":"(Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, 2009). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0."},{"key":"ref_14","unstructured":"European Medicines Agency (EMA) (2025, October 25). Rydapt (Midostaurin): EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rydapt-epar-product-information_en.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2023-190128","article-title":"Real-world outcomes using front-line midostaurine in combination with intensive chemotherapy for patients aged \u226560 years with FLT3-mutated acute myeloid leukemia","volume":"142","author":"Requena","year":"2023","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1177\/10781552211020815","article-title":"Real world use of FLT3 inhibitors for treatment of FLT3+ acute myeloid leukemia (AML): A single center, propensity-score matched, retrospective cohort study","volume":"28","author":"Bazzell","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1007\/s00277-019-03795-8","article-title":"Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study","volume":"98","author":"Berger","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.3324\/haematol.2022.281967","article-title":"Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia","volume":"108","author":"Lee","year":"2023","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jha2.1045","article-title":"A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real-world practice","volume":"5","author":"Messina","year":"2024","journal-title":"EJHaem"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"20420986241284105","DOI":"10.1177\/20420986241284105","article-title":"A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"Zhou","year":"2024","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e000606","DOI":"10.1136\/esmoopen-2019-000606","article-title":"European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis","volume":"4","author":"Tzogani","year":"2019","journal-title":"ESMO Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.bbmt.2011.02.003","article-title":"Role of allogeneic transplantation for FLT3\/ITD acute myeloid leukemia: Outcomes from 133 consecutive newly diagnosed patients from a single institution","volume":"17","author":"DeZern","year":"2011","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_23","first-page":"467","article-title":"Prognostic impact of NPM1\/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international RATIFY study","volume":"130","author":"Thiede","year":"2017","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/854\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:08:38Z","timestamp":1768986518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/2\/854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["jcm15020854"],"URL":"https:\/\/doi.org\/10.3390\/jcm15020854","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]}}}